The challenge for Regeneron Pharmaceuticals, Inc.’s CD20xCD3-targeting bispecific antibody odronextamab is to stand out in an increasingly crowded class that already has multiple approved agents, which data presented at the American Society of Hematology annual meeting suggest it may be able to do with a favorable toxicity profile, especially in terms of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Key Takeaways
-
Regeneron presented data for CD20xCD3-directed bispecific antibody odronextamab in diffuse large B-cell lymphoma at ASH, showing a 52% ORR and a 31% CR rate.
The Tarrytown, NY-based drug maker presented data from the Phase II ELM-2 study for odronextamab in DLBCL at the ASH...
